Alcosta Capital Management’s Boston Scientific BSX Stock Holding History

Alcosta Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-47,742	Closed	-$4.66M	–	27
2025 Q3	$4.66M	Sell	47,742 -685	-1%	-$70.9K	2.51%	22
2025 Q2	$5.2M	Buy	+48,427	New	+$4.9M	2.9%	18

Other funds holding BSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Alcosta Capital Management's BSX Position: Q4 2025 in Review

Alcosta Capital Management sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 47,742 shares — an estimated $4.66M sold.

Alcosta Capital Management first reported a position in BSX in Q2 2025 and held it in 2 quarters. The position peaked at $5.2M in Q2 2025. 1,795 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

Alcosta Capital Management reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
Alcosta Capital Management sold 47,742 Boston Scientific shares in Q4 2025, an estimated $4.66M.
Alcosta Capital Management first reported a position in Boston Scientific in Q2 2025 and held it in 2 quarters.
Alcosta Capital Management's Boston Scientific position peaked at $5.2M in Q2 2025.
1,795 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on Alcosta Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.